Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study-Reference-Cited by-同舟云学术

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

Published:2020-09-30 Issue:3 Volume:55 Page:139-145
ISSN:2287-979X
Container-title:BLOOD RESEARCH
language:en
Short-container-title:Blood Res

Author:

Gemelli Maria¹,Elli Elena Maria²,Elena Chiara³,Iurlo Alessandra⁴,Intermesoli Tamara⁵,Maffioli Margherita⁶,Pungolino Ester⁷,Carraro Maria Cristina⁸,D'Adda Mariella⁹,Lunghi Francesca¹⁰,Anghileri Michela¹¹,Polverelli Nicola¹²,Rossi Marianna¹³,Bacciocchi Mattia¹⁴,Bono Elisa³,Bucelli Cristina⁴,Passamonti Francesco⁶,Antolini Laura¹⁵,Gambacorti-Passerini Carlo²¹⁴

Affiliation:

1. Oncology Unit, San Gerardo Hospital, ASST-Monza, Monza, Italy

2. Hematology Division and Bone Marrow Unit, Ospedale San Gerardo, ASST-Monza, Monza, Italy

3. Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

4. Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

5. Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy

6. Hematology Unit, Ospedale di Circolo, Varese, Italy

7. Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

8. Hematology and Transfusional Medicine Unit, ASST Fatebenefratelli Sacco, Milan, Italy

9. Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy

10. Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, IRCCS Milano, Italy

11. Oncology Department, ASST Lecco, Lecco, Italy

12. Chair of Hematology, Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy

13. Department of Hematology, Cancer Center, IRCCS Humanitas Research Hospital/Humanitas University, Rozzano, Italy

14. Department of Medicine and Surgery, University of Milano-Bicocca, Italy

15. Center of Biostatistics for Clinical Epidemiology, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://pdf.medrang.co.kr/BR/2020/055/BR2055-03-04.pdf

Reference30 articles.

1. Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia – is it all BCR-ABL?

2. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

3. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

4. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

5. Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural compounds combined with imatinib as promising antileukemic therapy: An updated review;Fitoterapia;2024-10

2. Choice of Frontline Tyrosine‐Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A “Campus CML” Study;European Journal of Haematology;2024-09-12

3. Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy;Discover Oncology;2024-08-11

4. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

5. Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China;Therapeutic Advances in Hematology;2024-01